Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BT1718 |
Synonyms | |
Therapy Description |
BT1718 is a bicyclic peptide targeting MT1-MMP in conjugation with the maytansinoid tubulin inhibitor DM1, which may specifically target MT1-MMP-expressing tumor cells (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B135). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BT1718 | BT-1718|BT 1718 | BT1718 is a bicyclic peptide targeting MT1-MMP in conjugation with the maytansinoid tubulin inhibitor DM1, which may specifically target MT1-MMP-expressing tumor cells (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr B135). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03486730 | Phase Ib/II | BT1718 | BT1718 in Patients With Advanced Solid Tumours. | Completed | GBR | 0 |